About Histogenics
Histogenics is a publicly listed company based in Waltham (United States) founded in 2000. Restorative cell therapies for orthopedic diseases are developed. Histogenics has raised $115.72 million across 6 funding rounds from investors including Stryker, Gimv and Sofinnova. The company has 69 employees. Histogenics has completed 1 acquisition, including ProChon Biotech. Its focus areas include Life Sciences, Cell Therapy, Diversified and Orthopedics. Its legal entity is OCUGEN, INC. Its competitors include Tenaya Therapeutics, Athira Pharma and Ensoma; 3 of its 3 listed competitors have raised funding.
Company details
Histogenics was founded in 2000 and is headquartered in Waltham, United States. Focus is placed on the development of restorative cell therapies within the biotechnology sector, targeting orthopedic conditions. Operations center on proprietary regenerative technologies, including the flagship product NeoCart, by which patients knee cartilage is rebuilt using their own cells. Pain associated with cartilage damage is addressed directly, with potential to halt osteoarthritis advancement.
- Headquarters Waltham, United States
- Employees 69
- Stage Public
- SectorsHealthcare
- Website histogenics.com
- Social LinkedIn
- Legal Name Ocugen, Inc.
- Total Equity Funding$115.72M (USD)
in 6 rounds
- Latest Funding Round$30M (USD), Post-IPO
Sep 2016
- InvestorsStryker
& 7 more
- Employee Count69
- Investments & Acquisitions
Funding Insights of Histogenics
Histogenics has successfully raised a total of $115.72M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115.72M
- Total Rounds 6
- Last Round Post-IPO — $30M
- First Round $13.1M
(Aug 2006)
- Investors Count 8
All 6 funding rounds of Histogenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $30M | Post-IPO | – | – | – |
| Jan 2014 | $10.32M | Series C | – | – | – |
| Jul 2012 | $49M | Series C | – | Sofinnova Investments | |
| May 2011 | $34.3M | Series B | – | – | – |
| Sep 2008 | $9M | Series B | – | – | |
| Aug 2006 | $13.1M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Histogenics
Histogenics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Stryker, Gimv and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
US venture capital investments are made across all stages. | splitrock.com | Eden Prairie, United States | ||
US-focused private equity and venture capital investments are managed. | bostonmillenniapartners.com | Boston, United States | ||
Early-stage investments in telecom, IT, and e-commerce are targeted. | inflectpoint.com | Newark, United States | ||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Provides expert investment advisory services to clients. | 2004 | altimapartners.com | London, United Kingdom | |
3D-printed orthopedic products are manufactured for medical applications. | 1941 | stryker.com | Kalamazoo, United States | |
Offers data strategy, analytics, engineering, and consulting services to clients. | 2008 | iptpartners.com | Toronto, Canada |
Investor details for Histogenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Histogenics
3 people are tracked at Histogenics (2 in leadership, 1 in team); the tracked headcount is 69.
| Name | Role | Group |
|---|---|---|
Rich Vaillant | CFO | Leadership |
Nance Moran | Senior Director Program Management | Leadership |
Maria Fragoso | HR Manager | Team |
Complete people profiles for Histogenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Histogenics
Histogenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ProChon Biotech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Regenerative biology products for cartilage lesions are developed and commercialized. | prochon.com | Rehovot, Israel | 1996 | May 2011 | •••• |
Complete acquisition details for Histogenics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Histogenics
5 dated milestones of Histogenics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Histogenics is founded.
- Funding First funding round of $13.1M.
- Acquisition Acquires ProChon Biotech.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Histogenics
Histogenics has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Athira Pharma and Ensoma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| athira.com | 2011 | Seattle, United States | $121.04M | 62 | Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool |
Detailed competitors of Histogenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Histogenics
Websites that share an audience with Histogenics (histogenics.com).
Websites whose visitors overlap most with Histogenics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cerecor.com | 93% | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as Histogenics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Histogenics
Complete news archive for Histogenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Histogenics
Histogenics was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Histogenics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Histogenics is a funded company, having raised a total of $115.72M across 6 funding rounds to date. The company's 1st funding round was a Series A of $13.1M, raised on Aug 2006.
Histogenics has 69 employees.
Histogenics was founded in 2000 and is headquartered in Waltham, United States. Focus is placed on the development of restorative cell therapies within the biotechnology sector, targeting orthopedic conditions. Operations center on proprietary regenerative technologies, including the flagship product NeoCart, by which patients knee cartilage is rebuilt using their own cells. Pain associated with cartilage damage is addressed directly, with potential to halt osteoarthritis advancement.
Histogenics's top competitors include Tenaya Therapeutics, Athira Pharma and Ensoma.
Histogenics has made 1 acquisition, including ProChon Biotech.
Histogenics has 8 investors. Key investors include Stryker, Gimv, Sofinnova, Split Rock Partners, and Altima Partners.
Histogenics operates through Ocugen, Inc..